Keros Therapeutics (KROS) Earnings Date, Estimates & Call Transcripts $56.62 -3.73 (-6.18%) (As of 11/15/2024 ET) Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Keros Therapeutics Latest Earnings SummaryUpcoming Q4 Earnings DateFeb. 26EstimatedActual EPS (Nov. 6) -$1.41 Missed By -$0.13 Consensus EPS (Nov. 6) -$1.28 Keros Therapeutics posted Q3 2024 earnings on November 6, 2024, reporting an EPS of -$1.41, which missed the consensus estimate of -$1.28 by $0.13. Quarterly revenue rose 4750.0% year-over-year to $0.39 million. With a trailing EPS of -$5.21, Keros Therapeutics' earnings are expected to decrease next year, from ($5.28) to ($5.76) per share. KROS Upcoming EarningsKeros Therapeutics' next earnings date is estimated for Wednesday, February 26, 2025, based off prior year's reporting schedules. Get Keros Therapeutics Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Keros Therapeutics and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataKROS Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.KROS Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Ad Porter & CompanyFinancial Prophecy The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold $3 billion of Amazon… it’s why Nvidia’s CEO just sold $713 million... and it’s why Zuckerberg just sold $1.3 billion in Meta stock. The financial establishment doesn’t want you to know about this… but a controversial new documentary just pulled back the curtain and exposed what’s really going on. It’s called The Final Frontier.Including the name of the #1 company to buy. Keros Therapeutics Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20244-$1.34-$1.22-$1.26Q2 20244-$1.40-$1.15-$1.24Q3 20244-$1.47-$1.22-$1.32Q4 20244-$1.48-$1.30-$1.39FY 202416-$5.69-$4.89-$5.20Q1 20253-$1.51-$1.23-$1.39Q2 20253-$1.57-$1.18-$1.40Q3 20253-$1.54-$0.98-$1.29Q4 20253-$1.59-$0.77-$1.24FY 202512($6.21)($4.16)($5.32) Keros Therapeutics Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueLinks 2/26/2025(Estimated)------- 11/6/2024Q3 2024-$1.28-$1.41 -$0.13-$1.41-$0.39M8/7/2024Q2 2024-$1.23-$1.25 -$0.02-$1.25-$0.04M 5/8/2024Q1 2024-$1.33-$1.21+$0.12-$1.21-$0.08M 3/1/2024Q4 2023-$1.37-$1.34+$0.03-$1.34-$0.14M 11/6/2023Q3 2023-$1.35-$1.33+$0.02-$1.33-$0.01M 8/7/2023Q2 2023-$1.34-$1.27+$0.07-$1.27$0.22M- Get the Latest News and Ratings for KROS and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Keros Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 5/4/2023Q1 2023-$1.14-$1.26 -$0.12-$1.26$0.22M- 3/3/2023Q4 2022-$1.12-$1.09+$0.03-$1.09-- Keros Therapeutics Earnings - Frequently Asked Questions When is Keros Therapeutics's earnings date? Keros Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, February 26th, 2025 based off last year's report dates. Learn more on KROS's earnings history. Did Keros Therapeutics beat their earnings estimates last quarter? In the previous quarter, Keros Therapeutics (NASDAQ:KROS) missed the analysts' consensus estimate of ($1.28) by $0.13 with a reported earnings per share (EPS) of ($1.41). Learn more on analysts' earnings estimate vs. KROS's actual earnings. How much revenue does Keros Therapeutics generate each year? Keros Therapeutics (NASDAQ:KROS) has a recorded annual revenue of $150,000.00. How much profit does Keros Therapeutics generate each year? Keros Therapeutics (NASDAQ:KROS) has a recorded net income of -$152.99 million. KROS has generated -$5.21 earnings per share over the last four quarters. What is Keros Therapeutics's EPS forecast for next year? Keros Therapeutics's earnings are expected to decrease from ($5.28) per share to ($5.76) per share in the next year. ` More Earnings Resources from MarketBeat Related Companies SRRK Earnings YMAB Earnings AMRN Earnings FGEN Earnings MDGL Earnings ITCI Earnings ROIV Earnings ASND Earnings LEGN Earnings ELAN Earnings Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles MercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of EarningsLam Research Proves Analysts Wrong with a Strong Earnings ReportPulteGroup Earnings Signal Potential Entry Points for Investors Financial Prophecy (Ad)The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold $3 billion of Amazon… it’s why Nvidia’s CEO just sold $713 million... and it’s why Zuckerberg just sold $1.3 billion in Meta stock. The financial establishment doesn’t want you to know about this… but a controversial new documentary just pulled back the curtain and exposed what’s really going on. It’s called The Final Frontier.Including the name of the #1 company to buy. This page (NASDAQ:KROS) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Keros Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Keros Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free KROS Stock Alerts